UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 26, 2004
GENTA
INCORPORATED
(Exact Name of Registrant
as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 0-19635 | 33-0326866 | ||
| (Commission File Number) | (IRS Employer Identification No.) | ||
| Two
Connell Drive Berkeley Heights, NJ |
07922 | ||
| (Address of Principal Executive Offices) | (Zip Code) |
(908) 286-9800
(Registrant’s
Telephone Number, Including Area Code)
(Former Name or
Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other
Events.
On November
26, 2004 Genta Incorporated (“Genta”) issued a press release announcing
that the Company’s randomized Phase 3 clinical trial of Genasense® (oblimersen
sodium) Injection in patients with advanced multiple myeloma did not meet its primary
end-point. The trial had been designed to evaluate whether the addition of Genasense® to
standard therapy with high-dose dexamethasone could increase the time to
development of progressive disease in patients who previously had received
extensive therapy. Further details of the trial results will be presented on Saturday,
December 4, 2004 at the annual meeting of the American Society of Hematology (ASH)
in San Diego, CA. The press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
On November
29, 2004 Genta issued a press release announcing that Genasense® (oblimersen
sodium) Injection, the Company’s lead anticancer compound and Ganite® (gallium
nitrate injection) will be featured in several presentations at the annual meeting
of the American Society of Hematology (ASH) in San Diego, CA from December 3-7,
2004. Investigators will discuss study results in a variety of hematological cancers,
including chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma, acute
myeloid leukemia and multiple myeloma. The press release is attached hereto as
Exhibit 99.2 and incorporated herein by reference.
| Exhibit Number |
Description | |
| |
|
|
| 99.1 | Press Release dated November 26, 2004 | |
| 99.2 | Press Release dated November 29, 2004 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| GENTA INCORPORATED | ||||
| Date: | November 29, 2004 | By: | /s/ William P. Keane | |
| |
|
|||
| Name: |
William P. Keane | |||
| Title: | Vice President, Chief Financial Officer and Corporate Secretary | |||
EXHIBIT INDEX
| Exhibit Number |
Description |
Sequentially Numbered Page |
|
| 99.1 | Press Release dated November 26, 2004 | ||
| 99.2 | Press Release dated November 29, 2004 |